Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The goal of the REMNANT study is to confirm the clinical value of detecting a new biomarker, ctDNA (circulating tumor DNA), in the follow-up of patients with operated liver cancer. In order to meet this objective, this biomarker will be measured in your blood before and after surgery, at three and six months.
Hepatocellular carcinoma (HCC) is the most common primary liver cancer and develops in 80% of cases in the context of underlying cirrhosis1. Surgical resection, percutaneous destruction and liver transplantation are the three treatments considered curative with a non-negligible risk of recurrence of 35-50% at 2 years2.
Several data in the literature suggest that small subclinical tumors can be detected by circulating tumor DNA (ctDNA), and that the amount of tcDNA detected seems to correlate with risk factors for recurrence such as tumor size or microvascular invasion3, 4.
The objective of this pilot study is to evaluate the detection of ctDNA following tumor ablation and its impact on early recurrence.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Patient with hepatocellular carcinoma | Experimental | Circulating tumor DNA dosage will be done to patients with hepatocellular carcinoma |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| circulating tumor DNA dosage | Other | blood sample for circulating tumor DNA dosage will be done to patient with hepatocellular carcinoma |
|
| Measure | Description | Time Frame |
|---|---|---|
| Change in tcNA dosage between baseline and 6 Months | evolution of tcDNA percentage between Baseline and at 6 months after surgery | 6 months |
| Change in tcDNA dosage between baseline and 3 Months | evolution of tcDNA percentage between Baseline and at 3 months after surgery | 3 months |
| Measure | Description | Time Frame |
|---|---|---|
| Survival at 2 years | percentage of Survival 2 years after surgery | 2 years |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Edouard ROUSSEL, MD | Contact | +3323288 | 8610 | edouard.roussel@chu-rouen.fr |
| Julie RONDEAUX | Contact | +3323288 | 5427 | julie.rondeaux@chu-rouen.fr |
| Name | Affiliation | Role |
|---|---|---|
| Edouard ROUSSEL, MD | University Hospital, Rouen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Chu Rouen | Recruiting | Rouen | 76031 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006528 | Carcinoma, Hepatocellular |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D009369 | Neoplasms |
| D008113 | Liver Neoplasms |
| D004067 | Digestive System Neoplasms |
| D009371 | Neoplasms by Site |
| D004066 | Digestive System Diseases |
| D008107 | Liver Diseases |